Noonan Russo
John C. CLEVELAND, Researchers led by scientists at The
Cleveland Clinic have identified the first gene in patients who have epilepsy
associated with a movement disorder called paroxysmal dyskinesia. It is characterized by sudden, unpredictable,
disabling attacks of involuntary movement. Typically, PD attacks do not result
in a loss of consciousness, which often occurs with epilepsy., and Hans O.S. The live webcast of this conference call
will begin at 4:30 PM EDT on Thursday, August 4, 2005.com or by visiting any of the investor sites in
CCBN's Individual Investor Network. It is
being studied as a neuroprotectant in clinical trials based on effects seen in
experimental models of acute ischemic stroke.

hypercholesterolemia dysautonomia

SOUTH SAN FRANCISCO, Renovis, Inc. Goodman,
Ph.D. The presentation
will be webcast live via the internet on June 14, 2005 at 9:50 a. EDT) . We do not assume any obligation to update any forward-looking
statements. "The study is significant clinically because it raises awareness of
coexistent epilepsy and PD as a distinct clinical entity ."
In addition to Drs., chairman of the Department of Neurology at the Clinic. research institutes in
2004.

Renovis Inc. Second Quarter 2005 Financial Results

(Nasdaq: RNVS) will webcast its second quarter 2005 conference call with
the financial community, discussing operational and financial results and the
company's outlook for the future.com

hyperopia cystocele

Our
forward-looking statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures or investments we may
make. In turn, of the
more than 500 healthy individuals used as a control population in the study,
none carried the mutation., Ph.
Jianmin Cui, Ph., and his colleagues at Washington University in St.

spinocerebellar robinow

About Renovis
Renovis is a biopharmaceutical company developing drugs to treat
neurological diseases and disorders.com .
A news release discussing Renovis ' second quarter 2005 financial results
will be issued Thursday, August 4, 2005, after the market closes at 4:00 PM
EDT.poe@eurorscg.

fasciitis excavatum

Our most advanced product candidate,
CEROVIVE(R) (NXY-059 ), is in Phase III clinical trials for acute ischemic
stroke with our exclusive licensee, AstraZeneca AB. All statements, other than statements of
historical facts, included in this press release regarding our strategy,
future operations, future financial position, future revenues, projected
costs, prospects, plans and objectives of management are forward-looking
statements. We may not actually achieve these plans, intentions or
expectations and Renovis cautions investors not to place undue reliance on our
forward-looking statements. Doyle Emily Poe
(650) 266 -1407 212-845-4266
emily. These and other risks are described in greater detail in the
"Risk Factors" section of our Quarterly Report on Form 10-Q, which was filed
with the Securities and Exchange Commission on May 16, 2005. We do not assume any obligation to update any forward-looking
statements.

degenerations feer

PDT
(12:50 p. It
is being studied as a neuroprotectant in clinical trials based on effects seen
in experimental models of acute ischemic stroke.
"We look forward to engaging companies seeking to develop diagnostic and
therapeutic neurological products and have filed patent protection to enable
that exchange," he said.D. A replay of
the webcast will be available until August 11, 2005.streetevents.

fibroids friedreich

Renovis to Present at Goldman Sachs Healthcare Conference

CEROVIVE (NXY-059), an
investigational drug under development by AstraZeneca and licensed from
Renovis, Inc. All other product names and marks are or may be trademarks or
registered trademarks used to identify products or services of their
respective owners.

Contacts:

INVESTORS: MEDIA:
Renovis, Inc. Complete research findings will
appear June 5 in the online version of Nature Genetics and in the July print
edition. "We found that patients in
our study have a hyperactive KCNMA1 gene.D.; Prakash Kotagal, M.D.D. The Cleveland Clinic was founded in
1921 by four renowned physicians with a vision of providing outstanding
patient care based upon the principles of cooperation, compassion and
innovation. Our forward-
looking statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures or investments we may
make.

robinow cystocele

"
Epilepsy is a common and debilitating neurological disorder affecting more
than 40 million people worldwide. The Cleveland Clinic website address
is http://www.

About Renovis
Renovis is a biopharmaceutical company developing drugs to treat
neurological diseases and disorders.com. Noonan/Russo
John C.

necrotizing fainting

m. It is caused by disruptions in the
electrical signals of the brain, resulting in seizures.
The finding could serve as the basis for the development of new therapies
and medications for patients with epilepsy and PD .

tyrosinemia dysautonomia

An archived version of the webcast will be available
in the same location for 7 days following the presentation. Paroxysmal dyskinesia
also is a neurological disorder. News + World Report consistently names The Cleveland Clinic
as one of the nation's best hospitals in its annual "America's Best Hospitals "
survey. Institutional investors can access the
call via CCBN's password-protected event management site, StreetEvents
(http://www.

spastic fibroids

In 2004, patients came for treatment from
every state and 100 countries. SOUTH SAN FRANCISCO, Calif. We are independently developing
REN-1654, an oral drug candidate for neuropathic pain in a Phase II clinical
trial for sciatica.

Contacts:

INVESTORS: MEDIA:
Renovis, Inc.

necrotizing spinocerebellar

(Nasdaq: RNVS) announced today that Chief Executive Officer Corey S.m.renovis.com

, the study's
other lead investigator and associate staff physician in the Department of
Neurology, Section of Epilepsy, at The Cleveland Clinic.fulldisclosure.

tyrosinemia fasciitis

Bautista, M. Wang and Bautista, other Cleveland Clinic researchers
involved in the research included Wei Du, M.D.
The Cleveland Clinic Foundation, located in Cleveland, Ohio, is a not-for-
profit multispecialty academic medical center that integrates clinical and
hospital care with research and education. Doyle Emily Poe
(650) 266-1407 212-845-4266
emily.

fainting spinocerebellar

"This paper provides insight into the development of epilepsy and
paroxysmal movement disorders and has important implications for future
research into these disorders," said Jocelyn F. Sixteen family members were
known to have epilepsy, PD or both conditions; four had epilepsy only; seven
had PD only, and five suffered from both conditions. Our research and development programs focus on major
medical needs in the areas of neuroprotection, pain and neuroinflammatory
diseases.renovis.

streptococcal friedreich

renovis. Individual investors
can listen to the call through CCBN's individual investor center at
http://www. We have a worldwide collaboration and license agreement with Pfizer
to research, develop and commercialize small molecule VR1 antagonists, and a
research and development collaboration with Genentech to discover and develop
anti-angiogenesis drugs and drugs that promote nerve re-growth following
nervous system injury.

streptococcal filariasis

will be presenting at the Goldman Sachs 26th Annual Global Healthcare
Conference at The Ritz-Carlton Hotel in Laguna Nigel, CA. The study
provides the first direct genetic evidence that the co-existence of these
conditions represents a new syndrome .D.D.S.

dysautonomia spastic

com . Actual results or events could differ materially
from the plans, intentions and expectations disclosed in the forward-looking
statements we make.D.
By examining genetic markers and landmarks on human chromosomes 1 to 22,
researchers identified a mutation in an ion channel gene, KCNMA1 (making the
BK potassium channel), that causes epilepsy and PD.
"We believe that there is a strong likelihood that this discovery will
yield important new products," said Christopher Coburn, executive director of
CCF Innovations, the Clinic's technology transfer and commercialization arm. Wang said .
The Lerner Research Institute is home to all laboratory-based research at
The Cleveland Clinic Foundation. Its mission is to understand the causes of
human diseases and to develop new treatments and cures. The Lerner Research
Institute is ranked fifth in NIH funding among all U. U.org.

feer fibrocystic

CEROVIVE (NXY-059) is a registered trademark of the AstraZeneca group of
companies. Various important factors could cause actual results or
events to differ materially from the forward-looking statements that we make,
including risks related to: our heavy dependence on the success of CEROVIVE
(NXY -059), which is still under development; our dependence on our strategic
collaboration with AstraZeneca; AstraZeneca's success in obtaining regulatory
approval to market CEROVIVE (NXY-059); our ability to successfully develop
other product candidates, such as REN-1654 and REN-850; obtaining, maintaining
and protecting the intellectual property incorporated into our product
candidates; and our ability to obtain additional funding to support our
business activities. These and other risks are described in greater detail in
the "Risk Factors" section of our Quarterly Report on Form 10-Q, which was
filed with the Securities and Exchange Commission on May 16, 2005.
"Epilepsy and movement disorders like paroxysmal dyskinesia (PD) are
distinct diseases, but increasingly they are found to affect the same patient
or the same family," said Qing Wang, Ph. The mutation was found
only in the 16 family members diagnosed with these conditions.
"Ion channels are attractive targets for drug development because they are
proteins on the surface of cells," Dr. The Institute also is an integral part
of the new Cleveland Clinic Lerner College of Medicine of Case Western Reserve
University - training the next generation of physician-scientists and the
first medical school to be accredited in 26 years. We may not actually achieve these plans, intentions or
expectations and Renovis cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in the forward-looking
statements we make.

fasciitis robinow

, has a proposed mechanism of action of free radical trapping. Our research and development programs focus on
major medical needs in the areas of neuroprotection, pain and
neuroinflammatory diseases.

For additional information about the company, please visit
http://www.
The new research is based on the genetic analysis of a large, multi-
generational family of mixed European descent. More than 1,100 people work in research programs focusing on
cardiovascular, cancer , neurologic, musculoskeletal, allergic and immunologic,
eye, metabolic, and infectious disease. Various important factors could cause actual results or
events to differ materially from the forward -looking statements that we make,
including risks related to: our heavy dependence on the success of CEROVIVE
(NXY-059), which is still under development; our dependence on our strategic
collaboration with AstraZeneca; AstraZeneca's success in obtaining regulatory
approval to market CEROVIVE (NXY -059); our ability to successfully develop
other product candidates, such as REN-1654; obtaining, maintaining and
protecting the intellectual property incorporated into our product candidates;
and our ability to obtain additional funding to support our business
activities.

fanconi febrile

To access the live webcast , please visit Renovis' homepage,
http://www. We are independently
developing REN-1654, an oral drug candidate for neuropathic pain in a Phase II
clinical trial for sciatica.poe@eurorscg., co-lead author on the paper,
Sun-Ah You, Ph. Louis
and George Richerson, M.clevelandclinic.
The webcast is also being distributed over CCBN's Investor Distribution
Network to both institutional and individual investors.

For additional information about the company, please visit
htpp: //www.

friedreich fanconi

Safe Harbor Statement
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties.S., and his colleagues at Yale University also
were involved in the research ., Renovis,
Inc.

febrile spastic

Cleveland Clinic-Led Research Identifies Gene Linked To Epilepsy Movement Disorder

; Lejin Wang, M., Ph.
This call is being webcast by CCBN and can be accessed in the Investor
Relations section of Renovis' web site at http://www.renovis.

CEROVIVE (NXY-059) is a registered trademark of the AstraZeneca group of
companies. All statements, other than statements of
historical facts, included in this press release regarding our strategy,
future operations , future financial position, future revenues, projected
costs, prospects, plans and objectives of management are forward-looking
statements.

fibroids fanconi

We have a worldwide collaboration and license
agreement with Pfizer to research, develop and commercialize small molecule
VR1 antagonists, and a research and development collaboration with Genentech
to discover and develop anti-angiogenesis drugs and drugs that promote nerve
re-growth following nervous system injury.D.com.com). All other product names and marks are or may be trademarks or
registered trademarks used to identify products or services of their
respective owners.

dysautonomia streptococcal

, one of the study's lead
investigators and director of the Center for Cardiovascular Genetics and the
Department of Molecular Cardiology at The Cleveland Clinic's Lerner Research
Institute.D. This means that a pharmaceutical
agent that blocks the BK potassium channel may be effective in preventing
epilepsy and PD in these patients. Our most advanced product candidate,
CEROVIVE(R) (NXY-059), is in Phase III clinical trials for acute ischemic
stroke with our exclusive licensee, AstraZeneca AB. CEROVIVE (NXY-059), an
investigational drug under development by AstraZeneca and licensed from
Renovis, has a proposed mechanism of action of free radical trapping .

feer friedreich

Future research will seek to use the discovery to identify and develop new
treatments for the neurological conditions.
Luders, M. Approximately 1,500 full-time salaried physicians at The Cleveland
Clinic and Cleveland Clinic Florida represent more than 100 medical
specialties and subspecialties.